Current partner codePEPTIDESDE
NCT07551882·Phase 2·INTERVENTIONAL

Oxytocin Plus Self-compassion Training in Borderline Personality Disorder

Status

Recruiting

Phase

Phase 2

Enrollment

80

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

Background: Borderline personality disorder (BPD) is a frequentand serious psychiatric disorder characterized by a persistent pattern of instability in relationships, affect and self-image. Although long-term follow-up prospective studies have shown high clinical remission rates, they also point out that usually persist social functioning deficits, comorbidity, isolation, chronic affective clinic and life dissatisfaction. Self-compassion training (SCT) could be an effective strategy targeting self-criticism, shame and chronic feelings of worthlessness, as well as increasing resilience. In addition, the administration of intranasal oxytocin has proven useful in regulating social cognition, affiliation behaviors and enhancing empathy, key symptoms in this population. This combined intervention could be particularly appropriate for BPD patients. Objective: The objective of this project is to implement and evaluate the effectiveness of a combined intervention, based on SCT and intranasal oxytocin administration, for the treatment of patients with BPD. Methodology: Controlled and randomized clinical trial. A self-compassion training of 5 weeks duration plus intranasal oxytocin administration versus SCT plus placebo will be compared in a sample of 80 patients with BPD. Clinical and wellness measures will be evalutated as outcomes.

Full detailed description

Controlled clinical trial. A self-compassion training of 5 weeks duration plus intranasal oxytocin administration versus SCT plus placebo will be compared in a sample of 80 patients with BPD. Self-criticism, self-compassion, clinical and wellness measures will be evalutated as outcomes.

Interventions

Treatment arms and agents.

DRUG

Intranasal Oxytocin (IN-OXT)

24 UI oxytocin intranasal

DRUG

Intranasal Placebo

24 UI intranasal placebo

BEHAVIORAL

Self-Compassion Training (SCT)

SCT consists of a 5 sessions of Self-Compassions meditation training

Timeline

From registration to results.

  1. First posted

    Apr 27, 2026

  2. Study start

    Jan 10, 2024

  3. Primary completion

    Jun 1, 2026

  4. Study completion

    Aug 1, 2026

  5. Results posted

    Not reported

  6. Registry updated

    Apr 27, 2026

Outcomes

What the study measures.

Primary outcomes

Self Compassion Scale Short Form (SCS-SF)

Time frame · 1 month

Self-Compassion Scale (12 items, minimum 12-maximum 60). Higher scores worse

Secondary outcomes

Forms of Self-Criticism/Self-Attacking and Self-Reassuring Scale-Short Form (FSCRS-SF)

Time frame · 1 month

Self-reported Self-Criticism scale (14 items, minimum 0- maximum 56). Higher scores worse

Borderline Symptoms List-23 (BSL-23)

Time frame · 1 week

Self-reported Borderline Symptoms scale (minimum 0- maximum 92). Higher scores worse

Satisfaction with life scale (SWLS)

Time frame · 1 month

Self-reported satisfaction with life scale (SWLS), well being (5 items, minimum 5 - maximum 25). Higher scores better

Pemberton Happiness Index (PHI)

Time frame · 1 month

Pemberton Happiness Index (minimum 0 - maximum 110). Higher scores better

OMS WHO-QOL-BREF( WHOQOL-Group, 1998).

Time frame · 2 weeks

Quality of life OMS (26 items, minimum 26 - maximum 130). Higher scores better

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
50 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Diagnosis of Borderline Personality Disorder (BPD) according to two semi-structured interviews: the Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) and the Revised Diagnostic Interview for Borderlines (DIB-R). * Aged between 18 and 50 years, inclusive. * Pharmacological treatment stability maintained throughout the intervention period. * Previous treatment for BPD, specifically Standard Dialectical Behavior Therapy (DBT) or DBT Skills Training. * High levels of self-criticism, defined as scores \> 12 on the Inadequate Self (IS) subscale of the Forms of Self-Criticizing/Attacking \& Self-Reassuring Scale - Short Form (FSCRS-SF). Exclusion Criteria: * Presence of comorbid psychiatric disorders, including: Schizophrenia, Psychotic Disorders, Bipolar Disorder, Current Major Depressive Disorder (MDD), Substance Dependence, Organic Brain Disease, or Intellectual Disability, as determined by medical examination and clinical assessment using the SCID-I (Structured Clinical Interview for DSM-IV Axis I Disorders). * History of severe endocrine disorders. * History of medical conditions, specifically: Epilepsy, Renal Insufficiency (Kidney Failure), or Heart Failure. * Concurrent participation in any other psychotherapy or psychological treatment during the study period. * Women of childbearing potential who are unwilling or unable to use highly effective contraception (e.g., oral contraceptives, intrauterine device \[IUD\], partner's vasectomy, tubal ligation, or sexual abstinence) throughout the entire duration of the study. * Intention to become pregnant or planning a pregnancy during the course of the study. * Current pregnancy or breastfeeding at the time of enrollment or during the study. * Concomitant medical treatment that is incompatible with the administration of intranasal oxytocin.

Study locations

1 registered sites.

Spain. Showing up to 24 locations stored in the fast local snapshot.

Hospital de la Santa Creu i Sant Pau

Barcelona, Barcelona, Spain

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Oxytocin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.